Evidence map›Paper›PMID 22958924›Full record

ArticleCell stem cell2012

Distinct and dynamic requirements for mTOR signaling in hematopoiesis and leukemogenesis.

Alex Kentsis, A Thomas Look

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell stem cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Adaptive responses toProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. mTORC signaling in hematopoiesis.International journal of hematology · 2016
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alex Kentsis
A Thomas Look
Boston Children's Hospital · US

Funding

Aberrant activation of HGF/MET signaling as a therapeutic target in AMLK08CA160660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2011 to 2015
$768k
6 · The paper itself

Abstract

Signaling involving PI3K and AKT regulates cell growth, partly through the mTOR kinase complexes 1 and 2. In this issue of Cell Stem Cell, Kalaitzidis et al. and Magee et al. reveal unique requirements for mTORC1 and mTORC2 signaling during blood development and leukemogenesis induced by loss of PTEN.

Identifiers

PMID22958924
OpenAlexW2052515451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.